Gefapixant Tablets (Lifnua) is a selective P2X3 receptor antagonist classified as a cough treatment medication. Launched in Japan in April 2022, it is primarily indicated for the treatment of refractory chronic cough.
What are the Indications for Gefapixant Tablets (Lifnua)?
Main Indications
Gefapixant Tablets are indicated for the treatment of refractory chronic cough.
Refractory chronic cough refers to persistent cough symptoms in patients who have received adequate treatment for cough-related etiologies (such as asthma, gastroesophageal reflux disease, upper airway cough syndrome, etc.).
Prerequisites for Use
According to the package insert, a comprehensive clinical evaluation (including medical history, occupational environment, and relevant examinations) should be conducted before using this medication, with reference to the latest clinical guidelines.
This medication should only be considered when the cough is confirmed to be "refractory" or "unexplained."
Precautions
This medication is for symptomatic treatment, not etiological treatment.
It should not be used blindly for a long period. Instead, it should be used rationally under the guidance of a doctor, with regular assessment of efficacy and safety.
Specifications and Properties of Gefapixant Tablets (Lifnua)
Pharmaceutical Specifications
Each Gefapixant Tablet contains 45 mg of the active ingredient—gefapixant citrate (calculated as gefapixant).
The medication is packaged in PTP blister packs, with 10 blisters per box and 10 tablets per blister, totaling 100 tablets per box.
Pharmaceutical Properties
Dosage Form and Appearance: This product is a round, film-coated tablet, pink in color.
Size and Weight: Each tablet has a diameter of approximately 10.4 mm, a thickness of approximately 5.3 mm, and a single tablet weight of approximately 463.5 mg.
Identification Mark: The surface of the tablet is engraved with the identification code "777" to facilitate identification by patients and medical staff.
Excipient Composition
In addition to the active ingredient, this product contains various pharmaceutical excipients, including microcrystalline cellulose, D-mannitol, hypromellose, crospovidone, light anhydrous silicic acid, sodium stearyl fumarate, magnesium stearate, titanium dioxide, triacetin, iron oxide red, carnauba wax, etc. These excipients contribute to the tablet's formation, stability, and oral adaptability.
Storage Methods for Gefapixant Tablets (Lifnua)
Storage Conditions
Gefapixant Tablets should be stored at room temperature, protected from high temperature, moisture, and direct sunlight.
Refrigeration is not required, but the medication should be kept out of the reach of children.
Shelf Life
The shelf life of this product is 48 months from the date of manufacture.
Patients should use the medication within the shelf life indicated on the packaging. Do not take it after expiration.
Medication Reminder
(1) This product is a prescription drug and must be used with a doctor's prescription.
(2) When delivering the medication, patients should be specially reminded: the tablets must be removed from the PTP blister pack before administration to avoid accidental ingestion of the aluminum foil, which may cause serious complications such as esophageal mucosal injury or even perforation.
